Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Nov 28;7(22):7139-7140.
doi: 10.1182/bloodadvances.2023011400.

Ibrutinib in the treatment of relapsed FL and MZL?

Norbert Schmitz  1 , Imke E Karsten  1
Affiliations
Editorial

Ibrutinib in the treatment of relapsed FL and MZL?

Norbert Schmitz et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Comment on

Similar articles

See all similar articles

References

    1. Nastoupil L, Hess G, Pavlovsky MA, et al. Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma. Blood Adv. 2023;7(22):7141–7150. - PubMed
    1. Casulo C, Barr PM. How I treat early-relapsing follicular lymphoma. Blood Adv. 2019;133(14):1540–1547. - PubMed
    1. Rivero A, Mozas P, Magnano L, López-Guillermo A. Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review. Front Oncol. 2023;13 - PMC - PubMed
    1. Bartlett NL, Costello BA, LaPlant BR, et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood Advances. 2018;131(2):182–190. - PMC - PubMed
    1. Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188–1199. - PMC - PubMed